Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope

Cancer Science

Volumn 101, Issue 1, 2010, Pages 201-209

  Uchiyama, Susumu ^a   Suzuki, Yasuhiko ^b   Otake, Kentaro ^a   Yokoyama, Masami ^a   Ohta, Mitsuo ^a   Aikawa, Shuichi ^a   Komatsu, Midori ^c   Sawada, Tetsuji ^c   Kagami, Yoshitoyo ^d   Morishima, Yasuo ^d   Fukui, Kiichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY OUBM3; MONOCLONAL ANTIBODY OUBM3 H2; MONOCLONAL ANTIBODY OUBM6; MONOCLONAL ANTIBODY OUBM7; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BINDING AFFINITY; BURKITT LYMPHOMA; CANCER CELL CULTURE; CELLULAR IMMUNITY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOTOXICITY; DISSOCIATION CONSTANT; DRUG PROTEIN BINDING; DRUG SENSITIVITY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPHOCYTE DEPLETION; LYMPHOMA CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIGENS, CD20; APOPTOSIS; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HUMANS; MICE;

EID: 71849086634     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01392.x     Document Type: Article

References (52)

1. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994, 15:450-4.
2. Bubien JK, Zhou LJ, Bell PD, Frizzel RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2 + conductance found constitutively in B lymphocytes. J Cell Biol 1993, 121:1121-32.
3. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J Biol Chem 2003, 278:42427-34.
4. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002, 107:176-82.
5. Deans JP, Schieven GL, Shu GL. Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-γ1 and PLC phospholipase C-γ2. J Immunol 1993, 151:4494-504.
6. Pulczynski S, Boesen AM, Jensen OM. Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells-an immunofluorescence and immunoelectron microscopy study. Leuk Res 1994, 18:541-52.
7. Maloney DG, Liles TM, Czerwinski DK. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994, 84:2457-66.
8. Maloney DG, Press OW. Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. Oncology 1998, 10:63-76.
9. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91:1644-52.
10. Cardarelli PM, Quinn M, Buckman D. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002, 51:15-24.
11. Mathas S, Rickers A, Bommert K, Dörken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2002, 60:7170-6.
12. Taji H, Kagami Y, Okada Y. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998, 89:748-56.
13. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000, 26:133-43.
14. Chan HT, Hughes D, French RR. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003, 63:5480-9.
15. Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61:5137-44.
16. Reff ME, Carner K, Chambers KS. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-45.
17. Manches O, Lui G, Chaperot L. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-54.
18. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-6.
19. Cartron G, Dacheux L, Salles G. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcγ RIIIa gene. Blood 2002, 99:754-8.
20. Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006, 176:2600-9.
21. Anderson DR, Grillo-López A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Tans 1997, 25:705-8.
22. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007, 44:3823-37.
23. McLaughlin P, Grillo-Lopez AJ, Link BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-33.
24. Czuczman MS. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268-76.
25. Coiffier B, Lepage E, Briere J. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-42.
26. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-7.
27. Racila E, Link BK, Weng WK. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008, 14:6697-703.
28. Terui Y, Mishima Y, Sugimura N. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Clin Cancer Res 2009, 15:2523-30.
29. Hiraga J, Tomita A, Sugimoto T. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009, 113:4885-93.
30. Nishida M, Usuda S, Okabe M. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Int J Oncol 2007, 31:29-40.
31. Nishida M, Teshigawara K, Niwa O. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions. Int J Oncol 2008, 32:1263-74.
32. Deans JP, Polyak MJ. FMC7 is an epitope of CD20. Blood 2008, 111:2492.
33. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002, 99:3256-62.
34. Akao Y, Seto M, Takahashi T. Rearrangements on chromosome 11q23 in hematopoietic tumor-associated t(11;14) and t(11;19) translocations. Cancer Res 1991, 51:6708-11.
35. Hale G, Clark M, Waldmann H. Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 1985, 134:3056-61.
36. Suzuki E, Umezawa K, Bonavida B. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis. Oncogene 2007, 26:6184-93.
37. Johnson NA, Savage KJ, Ludkovski O. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009, 114:3533-37.
38. Czuczman MS, Olejniczak S, Gowda A. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res 2008, 14:1561-70.
39. Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res 2008, 14:1550-60.
40. Teeling JL, French RR, Cragg MS. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004, 104:1793-800.
41. Teeling JL, Mackus WJ, Wiegman LJ. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006, 177:362-71.
42. Cragg MS, Morgan SM, Chan HT. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003, 101:1045-52.
43. Li H, Ayer LM, Polyak MJ. The CD20 calcium channel is localized to microvilli and constitutively associated with membrane rafts: antibody binding increases the affinity of the association through an epitope-dependent cross-linking-independent mechanism. J Biol Chem 2004, 279:19893-901.
44. Bindon CI, Hale G, Waldmann H. Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies. Eur J Immunol 1988, 18:1507-14.
45. Golay J, Lazzari M, Facchinetti V. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001, 98:3383-9.
46. Golay J, Zaffaroni L, Vaccari T. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000, 95:3900-8.
47. Terui Y, Sakurai T, Mishima Y. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 2006, 97:72-9.
48. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001, 98:1352-7.
49. Lippow SM, Wittrup KD, Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol 2007, 25:1171-6.
50. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 2006, 177:1129-38.
51. Niwa R, Natsume A, Uehara A. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods 2005, 306:151-60.
52. Lazar GA, Dang W, Karki S. Engineered antibody Fc mutants with enhanced effector function. Proc Natl Acad Sci U S A 2006, 103:4005-10.